Overview
Are You Ready? DOACs for Pediatric Patients with Venous Thromboembolism
CME Touchpoint Digital Newsletter
Click the "View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this CME Touchpoint, leading pediatric cardiology expert, Riten Kumar, MD, MSc highlights the latest data on pediatric VTE and the role of DOACs. This interactive, engaging newsletter also expresses relevant dosing and administration considerations with the DOACs in the pediatric population.
This activity is intended for pediatricians, pediatric hospitalists, pediatric hematologists, and pediatric pulmonologists and cardiologists.
Clinicians need to stay abreast of the latest data with the DOACs in pediatric patients with or at risk for VTE. This education helps clinicians outline the epidemiology and risk factors of VTE in children, assess the most recent data with the DOACs for the pediatric population, and indicate current dosing and administration considerations with the DOACs in pediatric patients.
Upon completion of this activity, participants will be able to:
• Describe the epidemiology and risk factors of venous thromboembolism in children
• Evaluate the most recent data with the DOACs for pediatric patients
• Assess present dosing and formulation considerations with the DOACs for the pediatric population
• Describe the epidemiology and risk factors of venous thromboembolism in children
• Evaluate the most recent data with the DOACs for pediatric patients
• Assess present dosing and formulation considerations with the DOACs for the pediatric population
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
Riten Kumar, MD, MSc
Director, Thrombosis and Anticoagulation
Associate Professor of Pediatrics
Harvard Medical School
Director, Thrombosis and Anticoagulation
Dana Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA
Director, Thrombosis and Anticoagulation
Associate Professor of Pediatrics
Harvard Medical School
Director, Thrombosis and Anticoagulation
Dana Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Riten Kumar, MD, MSc
Advisor/Review Panel Member: Bayer Pharmaceuticals
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education CME activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
